Should Tenecteplase Be Administered in This Patient?
Yes, administer intravenous thrombolysis with either alteplase or tenecteplase—prior antiplatelet combination therapy (aspirin plus P2Y12 inhibitor) is NOT a contraindication to thrombolytic therapy in acute ischemic stroke within 4.5 hours. 1
Key Guideline Recommendation
The 2018 AHA/ASA Guidelines explicitly state that IV alteplase is recommended for patients taking antiplatelet drug combination therapy (e.g., aspirin and clopidogrel) before stroke on the basis of evidence that the benefit of alteplase outweighs a probable increased risk of symptomatic intracranial hemorrhage (sICH) (Class I; Level of Evidence B-NR). 1
This is a Class I recommendation, meaning the benefit far outweighs the risk, and you should proceed with thrombolysis.
Alteplase vs Tenecteplase: Which to Choose?
While the guidelines establish alteplase as the standard, tenecteplase (0.4 mg/kg single IV bolus) might be considered as an alternative to alteplase (Class IIb; Level of Evidence B-R). 1
Evidence Supporting Tenecteplase:
The 2024 ORIGINAL trial (1,465 patients) demonstrated that tenecteplase 0.25 mg/kg was noninferior to alteplase for excellent functional outcome (mRS 0-1: 72.7% vs 70.3%), with similar safety profiles including identical rates of sICH (1.2% in both groups). 2
The 2025 GWTG-Stroke registry analysis (79,550 patients, including 9,465 receiving tenecteplase) showed no significant differences in effectiveness or safety outcomes between tenecteplase and alteplase in routine clinical practice. 3
Tenecteplase offers practical advantages: single bolus administration (vs 60-minute infusion), longer half-life, and greater fibrin specificity. 4, 5
Critical Safety Consideration
The probable increased risk of sICH with dual antiplatelet therapy is acknowledged but does NOT change the recommendation to treat. The guidelines specifically address this scenario because the mortality and morbidity benefits of thrombolysis outweigh the bleeding risk. 1
Practical Algorithm
- Confirm eligibility criteria are met (within 4.5 hours, BP <185/110 mmHg, no other contraindications)
- Do NOT withhold thrombolysis because of prior aspirin + P2Y12 inhibitor use
- Choose either:
- Alteplase 0.9 mg/kg (max 90 mg) over 60 minutes with 10% bolus, OR
- Tenecteplase 0.4 mg/kg (or 0.25 mg/kg based on ORIGINAL trial) as single bolus
- Monitor closely for hemorrhagic complications given dual antiplatelet therapy
- Do NOT administer additional antiplatelet or anticoagulant therapy for 24 hours after thrombolysis 1
Common Pitfall to Avoid
Do not delay or withhold thrombolysis to "wait and see" if the patient is on dual antiplatelets. Time is brain—every minute of delay worsens outcomes. The guidelines explicitly recommend proceeding despite the increased bleeding risk because the net clinical benefit remains strongly positive.
If mechanical thrombectomy is being considered, do not observe after IV thrombolysis to assess clinical response—proceed directly to thrombectomy if indicated (Class III: Harm). 1